Do you have stage III colon cancer? Have you already completed surgery? If so, you may qualify for a study that uses a blood test called ctDNA to determine your treatment and to monitor for recurrence.
Do you have metastatic renal cell carcinoma? If so, you may be able to take part in a research study collecting information about how your therapy is affecting your quality of life.
Have you been diagnosed with urothelial carcinoma? If so, you may be able to take part in a research study evaluation of an investigational treatment called FX-909 in cancer patients.
Do you have advanced or metastatic non small cell lung cancer, squamous cell carcinoma of the head and neck, colorectal cancer, or renal cell carcionma? Have you tried previous therapies that did not work? If so, you may be able to take part in this study. Investigational study drug is provided.
Are you between the ages of 40 and 75? Are you willing to give a one-time blood sample? If so, you may be able to take part in a research study that is being used to develop and validate blood tests for early cancer detection.
Do you have triple negative breast cancer? Have you had surgery following chemotherapy? You may be able to participate in a study to find out if stopping pembrolizumab infusions after surgery is just as effective at reducing your risk of cancer recurrence.
Are you over 60 and were recently diagnosed with mantle cell lymphoma? You may be able to participate in a research study to determine whether patients who reach complete disease remission after treatment with rituximab and zanubrutinib, will remain longer in remission with or without continuous zanubrutinib treatment.
Have you been diagnosed with B-cell post-transplant lymphoproliferative disorder (PTLD) after an organ transplant? Have you not yet received any type of treatment for this condition? Then you may be eligible for a study to look at the safety and effectiveness of tafasitamab and rituximab combination treatment for PTLD.
Have you been diagnosed with unfavorable risk prostate cancer? Are you looking for treatment options? If so, you may be able to participate in a clinical trial examining different treatment options for prostate cancer.
Have you been recently diagnosed with Acute Lymphoblastic Leukemia? If so, you may be able to take part in a research study to help us learn more about the effects of using Tyrosine Kinase Inhibitor (TKI), steroids and blinatumomab versus treatment with steroids, Tyrosine Kinase Inhibitor (TKI) and chemotherapy.